Your browser is no longer supported. Please, upgrade your browser.
Settings
NLNK NewLink Genetics Corporation daily Stock Chart
NLNK [NASD]
NewLink Genetics Corporation
Index- P/E- EPS (ttm)-2.29 Insider Own25.70% Shs Outstand30.63M Perf Week-27.34%
Market Cap370.32M Forward P/E- EPS next Y-2.48 Insider Trans0.00% Shs Float21.86M Perf Month87.73%
Income-66.70M PEG- EPS next Q-0.77 Inst Own56.80% Short Float25.38% Perf Quarter91.30%
Sales41.20M P/S8.99 EPS this Y-108.00% Inst Trans7.93% Short Ratio2.88 Perf Half Y-46.03%
Book/sh3.51 P/B3.44 EPS next Y12.10% ROA-41.20% Target Price24.40 Perf Year12.26%
Cash/sh- P/C- EPS next 5Y- ROE-55.00% 52W Range5.90 - 25.17 Perf YTD17.61%
Dividend- P/FCF- EPS past 5Y0.30% ROI-65.70% 52W High-54.11% Beta1.24
Dividend %- Quick Ratio5.00 Sales past 5Y80.40% Gross Margin- 52W Low95.76% ATR1.51
Employees122 Current Ratio5.00 Sales Q/Q420.00% Oper. Margin- RSI (14)55.41 Volatility14.54% 12.99%
OptionableYes Debt/Eq0.00 EPS Q/Q48.90% Profit Margin- Rel Volume2.77 Prev Close12.09
ShortableYes LT Debt/Eq0.00 EarningsOct 27 BMO Payout- Avg Volume1.93M Price11.55
Recom1.40 SMA2015.57% SMA5039.73% SMA200-8.29% Volume1,319,404 Change-4.47%
Sep-11-17Reiterated Stifel Buy $14 → $29
Sep-08-17Upgrade Robert W. Baird Neutral → Outperform $8 → $22
Sep-08-17Upgrade Jefferies Hold → Buy
Jun-08-17Downgrade Robert W. Baird Outperform → Neutral $25 → $8
Mar-30-17Upgrade SunTrust Hold → Buy
May-11-16Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
May-10-16Reiterated Stifel Buy $63 → $23
May-10-16Reiterated Mizuho Buy $52 → $20
Mar-23-16Initiated Robert W. Baird Outperform $27
Mar-01-16Reiterated Mizuho Buy $62 → $52
Jul-15-15Reiterated Mizuho Buy $50 → $62
Jul-15-15Reiterated Cantor Fitzgerald Buy $44 → $62
May-06-15Reiterated Stifel Buy $59 → $63
Nov-07-14Reiterated Stifel Buy $51 → $55
Sep-12-14Initiated Mizuho Buy $50
Mar-31-14Reiterated MLV & Co Buy $29 → $45
Mar-03-14Downgrade Robert W. Baird Outperform → Neutral
Jan-22-14Reiterated Stifel Buy $31 → $53
Dec-13-13Reiterated Stifel Buy $28 → $31
Sep-30-13Reiterated MLV & Co Buy $24 → $29
Sep-18-17 12:57PM  NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube
Sep-11-17 03:15PM  Analyst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside Benzinga -5.83%
08:42AM  NewLink Genetics (NLNK) Jumps: Stock Rises 29.9% Zacks
Sep-09-17 10:02AM  3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher? Motley Fool
Sep-08-17 04:46PM  Why NewLink Genetics, Zumiez, and Everest Re Group Jumped Today Motley Fool +29.93%
01:12PM  Why NewLink Genetics Is Soaring 37.5% Higher Today Motley Fool
10:39AM  Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers TheStreet.com
09:50AM  Why NewLink Genetics Corporation (NLNK) Could Be A Buy Simply Wall St.
08:40AM  Options Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock Zacks
08:10AM  Today's Research Reports on Trending Tickers: AstraZeneca and NewLink Genetics ACCESSWIRE
Sep-07-17 06:10PM  3 Stocks Soaring Today GuruFocus.com +74.58%
01:01PM  Here's Why NewLink Genetics Is Vaulting 45% Higher Today Motley Fool
07:00AM  Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma Business Wire
Aug-29-17 07:00AM  NewLink Genetics to Participate in Upcoming Investor Conferences GlobeNewswire
Jul-28-17 11:35PM  NewLink reports 2Q loss Associated Press +10.00%
09:12AM  Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent TheStreet.com
08:00AM  NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program GlobeNewswire
06:15AM  Investor Network: Newlink Genetics Corporation to Host Earnings Call ACCESSWIRE
Jul-27-17 07:00AM  NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802 GlobeNewswire
Jul-12-17 02:48PM  ETFs with exposure to NewLink Genetics Corp. : July 12, 2017 Capital Cube
Jul-10-17 07:00AM  NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs GlobeNewswire
Jul-07-17 07:00AM  NewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference Call on July 28, 2017 GlobeNewswire
Jun-23-17 07:00AM  Positive Phase 1b Data for NewLink Genetics IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, Spain GlobeNewswire
Jun-21-17 03:43PM  These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop? Motley Fool +9.04%
Jun-19-17 08:00AM  A Surprising Disappointment Derails NewLink Genetics -- What's Next? Motley Fool
Jun-13-17 08:49AM  Are Options Traders Betting on a Big Move in NewLink (NLNK) Stock? Zacks
Jun-09-17 04:27PM  Roche-NewLink Drug Move Shouldn't Impact Incyte, Says Analyst Investor's Business Daily
Jun-08-17 05:03PM  Why Sina, Eldorado Gold, and NewLink Genetics Slumped Today Motley Fool -41.24%
04:20PM  Stocks Pull Off Narrow Win, But These Four Soared To New Highs Investor's Business Daily
02:28PM  Why Is NewLink Genetics Losing One-Third of Its Value Today? Motley Fool
09:20AM  NewLink Genetics Sinks After Regaining Licensing Rights for Its Cancer Treatment 24/7 Wall St.
09:20AM  Biotech Movers: NewLink, Inovio, Juno TheStreet.com
08:56AM  NewLink Genetics' stock plunges as Genentech plans to returns rights cancer treatment candidate MarketWatch
07:00AM  NewLink Genetics to Regain Rights to GDC-0919 GlobeNewswire
Jun-05-17 04:50PM  Why Herbalife, JinkoSolar, and NewLink Genetics Slumped Today Motley Fool -12.39%
09:25AM  Biotech Movers: Loxo, NewLink, BioCryst TheStreet.com
09:00AM  NewLink Genetics Indoximod + PROVENGE® Results in Statistically Significant Improvement in Radiographic Progression-Free Survival (rPFS) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) in Phase 2 Trial GlobeNewswire
Jun-02-17 04:01PM  Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer GlobeNewswire
06:56AM  Cancer drug prices could double or triple thanks to this popular but unproven drug trend MarketWatch
May-30-17 09:35AM  Update in Lawsuit for Investors in NewLink Genetics Corp (NASDAQ: NLNK) Shares Announced by Shareholders Foundation Accesswire -9.21%
May-18-17 05:32PM  Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer Investor's Business Daily -9.07%
03:33PM  Biotech Stocks: Is ASCO Much Ado About Nothing? Barrons.com
06:00AM  Data from Clinical Study of NewLink Genetics IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress GlobeNewswire
May-17-17 05:05PM  Data from Clinical Studies of NewLink Genetics Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017 GlobeNewswire
May-15-17 09:00PM  Newman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation - NLNK Business Wire
May-11-17 05:14PM  ETFs with exposure to NewLink Genetics Corp. : May 11, 2017 Capital Cube
May-09-17 10:52AM  NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 Capital Cube
May-08-17 07:00AM  NewLink Genetics to Participate in Upcoming Investor Conferences GlobeNewswire
May-05-17 08:22AM  3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month Motley Fool
May-04-17 09:21AM  NewLink reports 1Q loss Associated Press
08:00AM  NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance GlobeNewswire
07:20AM  Investor Network: Newlink Genetics Corporation to Host Earnings Call Accesswire
May-03-17 07:16PM  Lifshitz & Miller LLP Announces Investigation of Bingo Nation Inc., BofI Holding, Inc., Corbus Pharmaceuticals Holdings, Inc., Lion Biotechnologies, Inc., NewLink Genetics Corporation, Power Solutions International, Inc., Walter Investment Management Corp. and XBIOTECH INC. PR Newswire
Apr-25-17 12:34AM  Vaunted Ebola Vaccine Faces Questions The Wall Street Journal
Apr-24-17 06:23PM  Vaunted Ebola Vaccine Faces Questions The Wall Street Journal
Apr-21-17 03:41PM  NewLink Genetics Corp. Value Analysis (NASDAQ:NLNK) : April 21, 2017 Capital Cube
12:02PM  Should Gilead Sciences Acquire NewLink Genetics? Motley Fool
07:00AM  NewLink Genetics Announces Presentation of Two Abstracts at ASCO GlobeNewswire
Apr-20-17 08:20AM  NewLink Genetics Corp. breached its 50 day moving average in a Bullish Manner : NLNK-US : April 20, 2017 Capital Cube
Apr-13-17 12:01PM  Morgan Stanley Ups Incyte Target to $150 Barrons.com
10:41AM  The IDO-Inhibitor Race Is On to Improve Cancer Treatment Motley Fool
08:00AM  NewLink Genetics to Host Its First Quarter 2017 Financial Results Conference Call on May 4, 2017 GlobeNewswire
Apr-07-17 05:08PM  ETFs with exposure to NewLink Genetics Corp. : April 7, 2017 Capital Cube -7.70%
10:17AM  NewLink Genetics Corp. breached its 50 day moving average in a Bearish Manner : NLNK-US : April 7, 2017 Capital Cube
Apr-05-17 04:56PM  Why NewLink Genetics, Harmonic, and Innophos Holdings Slumped Today Motley Fool -14.00%
Apr-04-17 05:07PM  Why NewLink Genetics Shares Fell 10.3% Today Motley Fool -9.96%
04:02PM  NEWLINK GENETICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In NewLink Genetics Corporation (NLNK) To Contact The Firm Business Wire
09:48AM  NewLink Genetics Corp. stock drops 28% on mid-stage results for melanoma drug MarketWatch
08:30AM  Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda® (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary GlobeNewswire
Mar-31-17 09:30AM  TrovaGene and NewLink Genetics Find Investors Optimistic About Products Accesswire
Mar-30-17 04:07PM  NewLink Genetics' shares surge after upgrade, seen as takeover target CNBC +5.62%
10:33AM  5 Top Performing Stocks of the Best ETF of Q1 Zacks
07:08AM  NewLink Genetics upgraded by SunTrust
Mar-20-17 08:34AM  NEWLINK GENETICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Di
Mar-17-17 08:15AM  Blog Coverage PTC Therapeutics Acquires Rights for Duchenne Muscular Dystrophy Drug from Marathon for $140 Million Upfront Accesswire
Mar-10-17 01:04PM  NEWLINK GENETICS CORP Financials
Mar-07-17 01:23PM  NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Capital Cube -5.21%
Mar-06-17 02:16PM  NEWLINK GENETICS CORP Files SEC form 10-K, Annual Report
07:04AM  Four Companies Breaking Out Right Now With Record Growth
Mar-01-17 05:30PM  NEWLINK GENETICS CORP Files SEC form 8-K, Other Events +6.81%
05:05PM  NewLink Genetics Announces Presentation of Two Abstracts at AACR GlobeNewswire
Feb-28-17 08:45AM  NewLink reports 4Q loss
08:35AM  NEWLINK GENETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
08:00AM  NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 NewLink Genetics Corp Earnings Release - Before Market Open
Feb-21-17 10:02AM  NewLink Genetics (NLNK): Moving Average Crossover Alert
Feb-20-17 07:00AM  NewLink Genetics to Host Its Fourth Quarter and Year End 2016 Financial Results Conference Call on February 28, 2017 GlobeNewswire
Feb-13-17 05:14PM  [$$] Cevec Pharma, NewLink Genetics Target Zika Through Licensing Deal at The Wall Street Journal
07:00AM  NewLink Genetics to Participate in 2017 SunTrust Orphan Drug Day on February 14th GlobeNewswire
Feb-10-17 03:25AM  Will NewLink Genetics (NLNK) Continue to Surge Higher?
Jan-18-17 03:40PM  Lifshitz & Miller Law Firm Announces Investigation of DaVita Inc., First NBC Bank Holdings Company, Fresenius Medical Care AG & Co. KGAA, Inotek Pharmaceuticals Corporation, Natural Health Trends Corp., NeoPhotonics Corporation, NewLink Gen PR Newswire
Jan-11-17 11:19AM  NewLink Genetics Corp. Value Analysis (NASDAQ:NLNK) : January 11, 2017 -5.80%
Jan-10-17 07:18AM  NewLink Genetics Corp. breached its 50 day moving average in a Bullish Manner : NLNK-US : January 10, 2017
Jan-09-17 04:45PM  Newman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation Business Wire +18.30%
Jan-05-17 05:17PM  NEWLINK GENETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
Dec-27-16 01:31PM  ETFs with exposure to NewLink Genetics Corp. : December 27, 2016
08:30AM  NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session
Dec-23-16 11:42AM  Shark Bites: We Knew Today Would Be Slow, but Come On +9.79%
Dec-20-16 01:49PM  Do Hedge Funds Love Western Asset Mortgage Capital Corp (WMC)? at Insider Monkey
Dec-16-16 02:06PM  ETFs with exposure to NewLink Genetics Corp. : December 16, 2016
NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. Its portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. The company is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer (NSCLC); and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors. Its clinical development products include NLG2101 for metastatic breast cancer; NLG2102 for refractory malignant brain tumors; NLG2103 for advanced melanoma; NLG2104 for metastatic pancreatic cancer; NLG2105 for pediatric patients with refractory malignant brain tumors; and NLG2106 for acute myelogenous leukemia. The company's HyperAcute cellular immunotherapy product candidates under clinical development include tergenpumatucel-L, is being investigated in Phase Ib/II clinical trial for patients with advanced NSCLC; and dorgenmeltucel-L, is being investigated in a Phase II clinical trial for patients with advanced melanoma. Its infectious disease program includes replication-competent recombinant vesicular stomatitis virus, a vaccine technology to treat Ebola and Marburg viruses. The company has license and collaboration agreements with Genentech, Inc. and Merck, Sharpe and Dohme Corp. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Langren Carl W.Principal Accounting OfficerDec 14Sale10.853,94342,78210,691Dec 16 05:53 PM